On Friday, Standard BioTools Inc (NASDAQ: LAB) opened lower -6.86% from the last session, before settling in for the closing price of $1.75. Price fluctuations for LAB have ranged from $1.21 to $3.04 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -1.02% over the past five years. Company’s average yearly earnings per share was noted 62.06% at the time writing. With a float of $360.48 million, this company’s outstanding shares have now reached $372.26 million.
Let’s look at the performance matrix of the company that is accounted for 539 employees. In terms of profitability, gross margin is 48.57%, operating margin of -81.68%, and the pretax margin is -79.83%.
Standard BioTools Inc (LAB) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Medical Devices industry is another important factor to consider. The insider ownership of Standard BioTools Inc is 3.23%, while institutional ownership is 75.18%. The most recent insider transaction that took place on Nov 12 ’24, was worth 123,098. Before that another transaction happened on Sep 09 ’24, when Company’s Former Officer proposed sale 45,851 for $2.00, making the entire transaction worth $91,725.
Standard BioTools Inc (LAB) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.06% per share during the next fiscal year.
Standard BioTools Inc (NASDAQ: LAB) Trading Performance Indicators
Check out the current performance indicators for Standard BioTools Inc (LAB). In the past quarter, the stock posted a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.89.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.71, a number that is poised to hit -0.06 in the next quarter and is forecasted to reach -0.20 in one year’s time.
Technical Analysis of Standard BioTools Inc (LAB)
Standard BioTools Inc (NASDAQ: LAB) saw its 5-day average volume 1.19 million, a negative change from its year-to-date volume of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 23.61%. Additionally, its Average True Range was 0.13.
During the past 100 days, Standard BioTools Inc’s (LAB) raw stochastic average was set at 19.77%, which indicates a significant increase from 9.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.00% in the past 14 days, which was lower than the 68.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.8655, while its 200-day Moving Average is $2.0852. Nevertheless, the first resistance level for the watch stands at $1.6850 in the near term. At $1.7400, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.7900. If the price goes on to break the first support level at $1.5800, it is likely to go to the next support level at $1.5300. The third support level lies at $1.4750 if the price breaches the second support level.
Standard BioTools Inc (NASDAQ: LAB) Key Stats
There are currently 372,259K shares outstanding in the company with a market cap of 606.78 million. Presently, the company’s annual sales total 106,340 K according to its annual income of -74,660 K. Last quarter, the company’s sales amounted to 44,970 K and its income totaled -26,940 K.
